Zevra Therapeutics, Inc. ZVRA Allowance for Doubtful Accounts Receivable (Current)
Allowance for Doubtful Accounts Receivable (Current) at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivable.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s allowance for doubtful accounts receivable (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s allowance for doubtful accounts receivable (current)?
- Zevra Therapeutics, Inc. (ZVRA) reported allowance for doubtful accounts receivable (current) of $0 in Q1 2026.
- What does allowance for doubtful accounts receivable (current) mean?
- This is the valuation allowance for current receivables that are considered uncollectible due to disputes, bankruptcy, or other non-payment issues. It serves as a buffer against potential losses from customer defaults. It is a critical indicator of the health of the company's accounts receivable portfolio.